Investor Alert

Dec. 11, 2019, 3:04 a.m. EST

Clostridium Vaccine Market Develop Rapidly: Valneva SE and Pfizer, Inc

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Dec 11, 2019 (Heraldkeepers) -- Clostridium is a gram-positive bacteria, which includes various human pathogens including causative agents of botulism and tetanus. Clostridium difficile infections are the most widely recognized cause of hospital-acquired infectious diarrhea, which necessitates for development of prevention vaccine for this disease. Clostridium difficile, produces an anaerobic toxin that is transmitted through fecal-oral route. Clostridium difficile infection is caused during antibiotic treatment or due to healthcare associated infection. It leads to asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation.

Increasing C. difficile infections at healthcare facilities and growing antibiotic resistance to treatment drugs are boosting the demand for development of prophylactic options, in order to reduce the risk of infection in vulnerable patients. A 2013 bulletin published from the Centers for Disease Control and Prevention (CDC) stated that Clostridium difficile is an urgent antibiotic-resistance threats in the U.S.

Click Here to Get Sample PDF Copy of Latest Research: https://www.coherentmarketinsights.com/insight/request-sample/2359

Growing occurrence and high prevalence of clostridium difficile infection is expected to drive growth of the global clostridium vaccine market during the forecast period. According to Centers for Disease Control and Prevention (CDC), in 2015, around 500,000 people in the U.S. suffered from clostridium difficile infection.

Moreover, according to National Center for Biotechnology Information (NCBI), in 2012, around 37,900 patients were suffering from clostridium difficile infection in Canada. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016, reported significant incidence of clostridium difficile infection in China.

However, there is no substitute therapies apart from antibiotics available for the treatment of clostridium difficile infection. In severe cases, the only option available is surgery, fecal microbiota transplant, and probiotics in case of recurrent clostridium difficile infection.

Key players in the market are focused on research and development activities for development of clostridium vaccine that can offer preventive measure in the clostridium difficile infection in near future. For instance, in January 2017, Pfizer announced phase II study of investigational clostridium difficile vaccine candidate: PF-06425090; for the prevention of C. difficile infection. This randomized phase II study was conducted to examine the safety, tolerability, and immunogenicity of the vaccine in healthy adults aged 65 to 85 years. In March 2017, Pfizer initiated the phase III study with around 16,000 volunteers.

Furthermore, in July 2016, Valneva SE announced the successful completion of its phase II clinical study for its prophylactic vaccine candidate VLA84 targeting on primary prevention of C. difficile infection (CDI).

View Detail Report with Complete Table of Content: https://www.coherentmarketinsights.com/ongoing-insight/toc/2359

Among regions, North America is expected to hold a dominant position in the global clostridium vaccine market and is expected to account for the largest market share during the forecast period. This growth is owing to increased prevalence of Clostridium difficile in the U.S. coupled with growing awareness regarding the adoption of preventive measurement in Clostridium difficile infection in this region.

For instance, according to CDC, in 2011, healthcare-associated infections (HAIs) caused by C. difficile were estimated to cause around half a million infections in the U.S. and caused deaths of around 29,000 within 30 days of the initial diagnosis.

High cost required for late stage testing and increased risk related to failure of vaccine candidate during the clinical trial studies is expected to hinder the global clostridium vaccine market growth over the forecast period.

For instance, in December 2017, Sanofi terminated its phase III C. difficile clinical trial studies, due to the results of an interim trial analysis, which stated low probability of success with its C. difficile candidate. Moreover, discontinuation of Sanofi's C. difficile vaccine program is expected to offer great future opportunity for Pfizer and Valneva to offer its vaccine to patients after getting the satisfactory regulatory approval in the future.

Key players operating in global clostridium vaccine market include Valneva SE and Pfizer, Inc.

(Exclusive discount on this report) https://www.coherentmarketinsights.com/insight/request-discount/2359

Global Clostridium Vaccine Market Taxonomy:

The global clostridium vaccine market is segmented on the basis of vaccine and region

By Vaccine

By Region

North America
Latin America
Asia Pacific
Middle East

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com


This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.